A phase Ib/II study of the polo-like kinase 1 (PLK1) inhibitor, onvansertib, in combination with FOLFIRI and bevacizumab for second-line treatment of patients with KRAS-mutated metastatic colorectal Cancer (mCRC).-MedSci.cn

A phase Ib/II study of the polo-like kinase 1 (PLK1) inhibitor, onvansertib, in combination with FOLFIRI and bevacizumab for second-line treatment of patients with KRAS-mutated metastatic colorectal Cancer (mCRC).

Ahn, DH; Ridinger, M; Erlander, M; Bekaii-Saab, TS; Lenz, HJ

JOURNAL OF CLINICAL ONCOLOGY, 2021; 39 (3):

科室
- - 订阅+
  - 更多科室
工具
服务